INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 41h ago
HOUSE PTR1h ago
SEC 13F1h ago
ROBINHOOD CHAIN1h ago
SEC FORM 4/Grant or awardVerified data

Campbell Shannon reported BDTX

Director · Black Diamond Therapeutics, Inc. · Black Diamond Therapeutics, Inc. — Stock Option (Right to Buy)

Side
A
Value
—
Shares
40.0K
Price
—
Executed
Jun 26, 2026
Disclosed
Jun 29, 2026
Disclosure timeline3 days from execution to publication · legal deadline 2 business days
Jun 26 executedJun 29, 2026 disclosed

BDTX · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+1 / 25

    No reported dollar value · new position

  • Filing timing0 / 15

    Disclosed 1 business day after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · BDTX

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    13
    RP
    Raman PrakashDirector
    BDTXBlack Diamond Therapeutics, Inc.
    Grant or award
    		A$13K
    6,801 sh
    		Sep 18, 2026Sep 21, 2026
    traded Sep 18, 2026
    		+3dSEC FORM 4

    Evidence

    9
    RP
    Raman PrakashDirector
    BDTXBlack Diamond Therapeutics, Inc.
    Grant or award
    		A—
    40.0K sh
    		Jun 26, 2026Jun 29, 2026
    traded Jun 26, 2026
    		+3dSEC FORM 4

    Evidence

    9
    KS
    Kulkarni SamarthDirector
    BDTXBlack Diamond Therapeutics, Inc.
    Grant or award
    		A—
    40.0K sh
    		Jun 26, 2026Jun 29, 2026
    traded Jun 26, 2026
    		+3dSEC FORM 4

    Evidence

    17
    RP
    Raman PrakashDirector
    BDTXBlack Diamond Therapeutics, Inc.
    Grant or award
    		A$13K
    7,907 sh
    		Jun 19, 2026Jun 22, 2026
    traded Jun 19, 2026
    		+3dSEC FORM 4

    Evidence

    13
    RP
    Raman PrakashDirector
    BDTXBlack Diamond Therapeutics, Inc.
    Grant or award
    		A$13K
    6,105 sh
    		Mar 20, 2026Mar 20, 2026
    traded Mar 20, 2026
    		+0dSEC FORM 4

    Evidence

    9
    BE
    Buck ElizabethCHIEF SCIENTIFIC OFFICER
    BDTXBlack Diamond Therapeutics, Inc.
    Grant or award
    		A—
    250.0K sh
    		Jan 21, 2026Jan 23, 2026
    traded Jan 21, 2026
    		+2dSEC FORM 4

    Evidence

    9
    VA
    Velleca Mark A.Director, PRESIDENT & CEO
    BDTXBlack Diamond Therapeutics, Inc.
    Grant or award
    		A—
    600.0K sh
    		Jan 21, 2026Jan 23, 2026
    traded Jan 21, 2026
    		+2dSEC FORM 4

    Evidence

    9
    YS
    Yurasov SergeyCHIEF MEDICAL OFFICER
    BDTXBlack Diamond Therapeutics, Inc.
    Grant or award
    		A—
    250.0K sh
    		Jan 21, 2026Jan 23, 2026
    traded Jan 21, 2026
    		+2dSEC FORM 4

    Evidence

    9
    JE
    Jones ErikaSEE REMARKS
    BDTXBlack Diamond Therapeutics, Inc.
    Grant or award
    		A—
    200.0K sh
    		Jan 21, 2026Jan 23, 2026
    traded Jan 21, 2026
    		+2dSEC FORM 4

    Evidence

    13
    RP
    Raman PrakashDirector
    BDTXBlack Diamond Therapeutics, Inc.
    Grant or award
    		A$13K
    4,665 sh
    		Dec 12, 2025Dec 15, 2025
    traded Dec 12, 2025
    		+3dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002018966-26-000007
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Jun 26, 2026
    Published
    Jun 29, 2026
    Ingested by INSIDER
    Nov 5, 03:50 UTC
    Last re-read
    Nov 5, 03:50 UTC

    Extracted facts

    Filer
    Campbell Shannon
    Role
    Director
    Transaction
    Grant or awardAs filed: “A”
    Asset
    Black Diamond Therapeutics, Inc. — Stock Option (Right to Buy)
    Ticker
    BDTX
    Shares
    40.0K
    Price per share
    $0
    Execution date (reported)
    Jun 26, 2026
    Owned after transaction
    40.0K shares
    Days from execution to publication
    3

    What this establishes

    Campbell Shannon filed this Form 4 reporting a grant or award of BDTX on Jun 26, 2026. It became public on Jun 29, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director
    Campbell Shannoncik:0002018966
    Issuer
    Black Diamond Therapeutics, Inc.cik:0001701541

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.